Finzati - Logo
GNPX logo

Genprex, Inc.

GNPXBiotechnology
$3.50
+0.08 (+2.19%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$2.18M
Growth
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 3.84Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:25 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$3.50
Change2.19%
Market Cap$2.18M
Beta-0.89
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio3.84
Quick Ratio3.84
Volume90.35K
Avg Volume73.77K

Investment DNA

How strong this company looks for long-term investors

47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score
Manageable debt level · 0Healthy liquidity · 3.84Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 3/29/2018
Industry: Biotechnology
P/B i: 0.21
Debt / Equity i: 0.00
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.00
Current Ratio: 3.84
Quick Ratio: 3.84
Status: Good

Insider Transactions

Recent executive and insider activity

LONGNECKER BRENT M
Transaction: 04/14/2026
SELL
Change
-10
Price
$1.23
Filing
04/15/2026
Type
SELL
Confer Ryan M.
Transaction: 02/27/2026
SELL
Change
-9,330
Price
$2.00
Filing
02/27/2026
Type
SELL
Berger Mark Stanley
Transaction: 02/27/2026
SELL
Change
-7,168
Price
$2.00
Filing
02/27/2026
Type
SELL